Research

rs7137828 — ATXN2

Intronic ATXN2 variant associated with primary open-angle glaucoma risk; T allele elevates odds of glaucoma by ~17% per copy through reduced retinal ganglion cell function

Strong Risk Factor Share

Details

Gene
ATXN2
Chromosome
12
Risk allele
T
Clinical
Risk Factor
Evidence
Strong

Population Frequency

CC
10%
CT
43%
TT
47%

See your personal result for ATXN2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ATXN2 and Glaucoma Risk — When an Aging Gene Threatens Vision

Ataxin-2 (ATXN2) encodes an RNA-binding protein best known for its role in spinocerebellar ataxia type 2, a neurodegenerative disorder caused by massive CAG repeat expansions in the gene. But common variants in ATXN2 tell a different story — one that intersects aging biology, RNA metabolism, and the health of the cells that let you see. The rs7137828 variant, sitting in an intron of ATXN2, has been robustly linked to primary open-angle glaucoma (POAG), the most common form of glaucoma and the leading cause of irreversible blindness worldwide.

The landmark 2016 meta-analysis11 The landmark 2016 meta-analysis
Cooke Bailey JN et al. Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma. Nat Genet. 2016
analyzed 5,990 glaucoma cases and 40,179 controls across U.S., Australian, European, and Singaporean cohorts. It identified rs7137828[T] as a genome-wide significant risk allele (OR=1.17, p=8.73×10⁻¹⁰), and showed that ATXN2 protein is expressed in retinal ganglion cells and the optic nerve head — the exact tissues that degenerate in glaucoma.

The Mechanism

A 2025 functional study22 A 2025 functional study
Shi Song Rong et al. ATXN2 loss of function results in glaucoma-related features supporting a role for Ataxin-2 in primary open-angle glaucoma pathogenesis. Vision Res. 2025
used CRISPR-edited zebrafish to establish how ATXN2 influences eye health. Fish lacking functional atxn2 developed reduced eye size, fewer retinal ganglion cells, elevated intraocular pressure (IOP), and impaired visual function — reproducing the hallmarks of human glaucoma in a model organism. Complementation assays confirmed that 14 human ATXN2 missense variants associated with POAG have genuine functional effects on the gene, pointing to a loss-of-function mechanism.

At the molecular level, ataxin-2 is a multifunctional RNA-binding protein. It regulates mRNA translation via the PI3K/mTOR pathway33 mRNA translation via the PI3K/mTOR pathway
Lastres-Becker I et al. Nat Commun. 2016
, assembles into stress granules during cellular stress, and modulates protein synthesis in response to nutrient deprivation. In retinal ganglion cells, which must maintain long axons all the way to the brain's lateral geniculate nucleus, this RNA metabolism role may be critical for sustaining cellular health across decades. A variant that subtly impairs ataxin-2 function — or alters its expression in relevant tissues — likely reduces the resilience of these non-regenerating neurons over time.

The Evidence

The glaucoma association for rs7137828 meets the highest standards of genetic evidence. The discovery OR of 1.17 per T allele (95% CI approximately 1.12–1.22) was replicated across multiple independent populations including European-American, Australian, and Singaporean cohorts.

A 2023 Brazilian replication44 A 2023 Brazilian replication
Rodrigues TAR et al. Ophthalmic Genet. 2023
confirmed the finding in 506 POAG cases and 501 controls: TT homozygotes faced nearly double the risk compared to CC homozygotes (OR=1.717, 95% CI 1.169–2.535, p=0.006). Even CT heterozygotes showed measurable differences in vertical cup-to-disk ratio (VCDR), a structural biomarker of glaucomatous damage, suggesting a dose-dependent effect on optic nerve morphology.

The variant's placement in the 12q24 chromosomal region is also notable for its connections to broader aging biology. An informed GWAS for exceptional longevity55 An informed GWAS for exceptional longevity
Fortney K et al. Genome-Wide Scan Informed by Age-Related Disease Identifies Loci for Exceptional Human Longevity. PLoS Genet. 2015
identified the SH2B3/ATXN2 locus as one of just four loci replicated at FDR < 5% for extreme longevity across centenarian cohorts, and noted that ATXN2's Drosophila ortholog extends lifespan when manipulated. The neighboring SH2B3 gene encodes LNK, a signaling adaptor that modulates cytokine and insulin receptor pathways — underscoring how this chromosomal region sits at the crossroads of immune regulation, metabolic aging, and now ocular health.

Practical Actions

POAG is particularly insidious because it causes painless, slow loss of peripheral vision that most people don't notice until substantial damage has occurred. The T allele adds a modest but real increment of lifetime risk on top of other glaucoma risk factors (age, elevated IOP, thin corneas, family history, African ancestry).

The most actionable implication is earlier and more vigilant eye pressure monitoring. Standard guidelines recommend comprehensive eye exams including IOP measurement every 1–2 years from age 40, but carriers of one or two T alleles — especially if combined with other risk factors — have reason to start earlier (age 35) and to specifically request optic nerve imaging (OCT). Caught early, glaucoma is highly manageable with topical medications or laser therapy; caught late, the vision loss is permanent.

Intraocular pressure is also modifiable: aerobic exercise consistently lowers IOP66 aerobic exercise consistently lowers IOP
Passo MS et al. Arch Ophthalmol. 1991
, and caffeine consumption acutely raises it. For carriers seeking to reduce modifiable risk, regular aerobic activity and monitoring of coffee intake may offer meaningful benefit.

Interactions

The rs7137828 ATXN2 variant sits within the 12q24 locus alongside rs3184504 in SH2B3, which encodes the LNK signaling adaptor and is the primary variant associated with longevity and cardiovascular protection at this locus. The two genes are distinct but biologically intertwined: SH2B3/LNK regulates hematopoietic and immune signaling, while ATXN2 regulates RNA metabolism and protein synthesis. Both contribute to the pleiotropic disease associations of 12q24 — covering autoimmune, cardiovascular, neurodegenerative, and now ocular conditions. Individuals carrying risk alleles at both rs7137828 (ATXN2, glaucoma) and rs3184504 (SH2B3, cardiovascular/longevity) may warrant particularly comprehensive health monitoring across multiple organ systems, though formal combined-risk studies have not been published.

ATXN2 also intersects with TDP-43 biology: intermediate CAG repeat expansions in ATXN2 (27–33 repeats, not yet disease-causing on their own) increase the risk of ALS by stabilizing TDP-43 aggregates. The common rs7137828 variant does not affect repeat length, but highlights ATXN2's biological proximity to RNA metabolism pathways that span glaucoma, neurodegeneration, and aging.

Genotype Interpretations

What each possible genotype means for this variant:

CC “Standard Risk” Normal

No elevated glaucoma risk from ATXN2

The CC genotype at rs7137828 represents the reference state: no additional glaucoma risk from this locus beyond what is expected for age, family history, and other environmental factors. ATXN2 is expressed in retinal ganglion cells and the optic nerve head, and the CC genotype preserves the baseline expression pattern associated with normal optic nerve function.

Note that the CC genotype is uncommon globally (~10%) due to the very high frequency of the T allele in African (~92%) and East Asian (~100%) populations, though it reaches ~23% in Europeans. Routine eye care with periodic IOP measurement from age 40 remains appropriate even without this genetic risk factor.

CT “One Risk Allele” Intermediate Caution

Modestly elevated glaucoma risk with one T allele

The T allele at rs7137828 was identified at genome-wide significance for POAG in a 2016 Nature Genetics meta-analysis across nearly 46,000 individuals. In a dose-dependent (additive) pattern, each T allele shifts glaucoma risk upward by ~17%. For CT heterozygotes, absolute lifetime risk remains modest but meaningfully elevated compared to CC individuals, particularly in the context of other risk factors (age over 60, elevated baseline IOP, thin central corneal thickness, family history of glaucoma, African ancestry).

The variant's mechanism involves ataxin-2's role in retinal ganglion cell biology. ATXN2 expression in these cells and at the optic nerve head suggests the T allele may subtly impair the gene's RNA metabolism and stress-response functions in precisely the tissue that degenerates in glaucoma — effects that accumulate slowly over decades.

TT “Two Risk Alleles” High Risk Warning

Higher glaucoma risk with two copies of the T allele

The TT genotype represents homozygosity for the glaucoma risk allele at rs7137828. The 2023 Brazilian replication study (506 POAG cases, 501 controls) found OR=1.717 (95% CI 1.169–2.535) for TT vs. CC, substantially higher than the per-allele OR of 1.17 seen in the larger multi-ancestry meta-analysis — consistent with additive or slightly super-additive effects of two risk alleles. Functional studies confirm ATXN2 operates via a loss-of-function mechanism in ocular tissue: zebrafish lacking atxn2 develop elevated intraocular pressure, reduced retinal ganglion cells, and impaired vision.

The TT genotype at rs7137828 is remarkably common globally (~47%) due to near-fixation of the T allele in East Asian (~100%) and African (~92%) populations, with ~27% frequency in Europeans. Population-level POAG prevalence is also higher in people of African descent, suggesting this variant may contribute to that disparity when combined with other risk factors.

Glaucoma caught at an early stage — before significant optic nerve damage — can be arrested with topical prostaglandin analogues, beta-blockers, or selective laser trabeculoplasty. The window for intervention is wide; the window for detecting subclinical damage before visual loss is narrower and requires imaging beyond routine pressure checks.